LLY : Analysis & Opinions

  1. Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook

    March 25, 2014
    Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
  2. This Recent Spin-Off Has 20% Upside

    January 17, 2014
    Who doesn't love to indulge with a sweet treat every now and then? (Especially when it's chocolate...) #-ad_banner-#​The ...
  3. The Simple Win-Win Strategy For Taming Risk In Your Portfolio

    January 17, 2014
    Risk is a fundamental part of investing. It might be easiest to understand by using bonds as an example.#-ad_banner-#​With ...
  4. Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook

    December 3, 2013
    Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
  5. Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook

    July 30, 2013
    Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook
  6. Qiagen Grows CDx Portfolio - Analyst Blog

    July 15, 2013
    Qiagen gains FDA approval for the therascreen EGFR test.
  7. Earnings Preview: J&J to Report In Line? - Analyst Blog

    July 15, 2013
    We expect Johnson & Johnson (JNJ) to report in line second-quarter 2013 results.
  8. Update on Threshold Pharma's TH-302 - Analyst Blog

    July 8, 2013
    Threshold Pharma announced an amendment in the protocol for its pivotal phase III study of TH-302
  9. Sanofi's Lyxumia Gets Japanese Nod - Analyst Blog

    July 2, 2013
    Sanofi announced that Lyxumia has been cleared by Japan's Ministry of Health, Labour and Welfare
  10. VIVUS' Spedra Gets EU Approval - Analyst Blog

    June 27, 2013
    VIVUS announced that the European Commission has cleared Spedra
  11. Stock Market News for June 27, 2013 - Market News

    June 27, 2013
    Weaker-than-expected GDP numbers eased investor concerns that the Federal Reserve would decrease monetary stimulus in the ...
  12. Encouraging Data on Sanofi's Lixisenatide - Analyst Blog

    June 25, 2013
    Sanofi presented positive data on its type II diabetes drug, lixisenatide
  13. Glaxo Presents Albiglutide Data - Analyst Blog

    June 25, 2013
    GlaxoSmithKline presented data from five phase III studies on albiglutide
  14. Positive Phase III Data on Sanofi's U300 - Analyst Blog

    June 24, 2013
    Sanofi announced encouraging data from two phase III studies evaluating U300.
  15. Lilly Alzheimer's Study Terminated - Analyst Blog

    June 14, 2013
    The phase II study was voluntarily terminated due to the identification of abnormal liver biochemical tests during routine ...
  16. CHMP Positive on Sanofi's Lantus - Analyst Blog

    June 11, 2013
    The Committee for Medicinal Products for Human Use issued a positive opinion related to Lantus
  17. Investing For The Global Diabetes Epidemic

    May 31, 2013
    Sadly, diabetes is quickly becoming a global epidemic. Within these grim statistics, investors can find opportunities with ...
  18. Mylan Extends Biocon Collaboration - Analyst Blog

    February 14, 2013
    Mylan (MYL) extended its three-year old partnership with India-based Biocon Limited. The companies recently signed a definitive ...
  19. Data on Peregrine's Bavituximab - Analyst Blog

    February 14, 2013
    Peregrine Pharmaceuticals (PPHM) recently announced phase II data on its oncology candidate, bavituximab. The open-label, ...
  20. Roche Collaborates with RQx Pharma - Analyst Blog

    February 13, 2013
    Roche (RHHBY) recently entered into a drug discovery collaboration with privately-held RQx Pharmaceuticals, Inc. through ...
  21. Shire Settles Lawsuit with Impax - Analyst Blog

    February 13, 2013
    Shire plc (SHPG) recently settled its pending litigation with Impax Laboratories, Inc. (IPXL). The litigation is related ...
  22. Cardiome Selects Quintiles - Analyst Blog

    February 12, 2013
    Cardiome Pharma Corp. (CRME) recently selected privately-held Quintiles for providing lifecycle safety and global regulatory ...
  23. Novo Nordisk Suffers Setback - Analyst Blog

    February 11, 2013
    Novo Nordisk (NVO) recently faced a setback when the US Food and Drug Administration (FDA) declined to approve its diabetes ...
  24. Update on Lilly's Tabalumab - Analyst Blog

    February 11, 2013
    Eli Lilly and Company (LLY) recently provided an update on its rheumatoid arthritis candidate, tabalumab. The company said ...
  25. SHPG Reaches Agreement with US Govt - Analyst Blog

    February 5, 2013
    Ireland-based Shire plc (SHPG) recently announced that the company has reached an agreement in principle to resolve the previously ...
  26. Generics Hurt AZN Results - Analyst Blog

    February 4, 2013
    AstraZeneca's (AZN) fourth-quarter 2012 core earnings of $1.56 per American Depositary Share (ADS) beat the Zacks Consensus ...
  27. Update on AGN's Acquisition of MAP - Analyst Blog

    February 1, 2013
    Allergan, Inc. (AGN) recently announced that it has commenced a cash tender offer to purchase all the shares of MAP Pharmaceuticals, ...
  28. Roche Grows in 2012 - Analyst Blog

    February 1, 2013
    Roche Holdings Ltd. (RHHBY) recently reported 2012 results. Revenues grew 4% year over year to CHF 45.5 billion driven by ...
  29. Strong 2012 Results at Novo Nordisk - Analyst Blog

    February 1, 2013
    Novo Nordisk (NVO) reported fourth quarter 2012 earnings of $1.83 per American Depository Receipt (ADR), up 21.2% from the ...
  30. Roche Teams Up With Afraxis - Analyst Blog

    January 30, 2013
    Roche (RHHBY) announced that its wholly owned subsidiary, Genentech, has recently inked a global licensing agreement with ...
  31. Stock Market News for January 30, 2013 - Market News

    January 30, 2013
    Better-than-expected quarterly results once again guided the S&P 500 and the Dow Jones into the green on Tuesday. Strong ...
  32. Favorable Ruling for Allergan - Analyst Blog

    January 29, 2013
    Allergan (AGN) received some positive news when the US Court of Appeals for the Federal Circuit ruled in its favor and found ...
  33. MedTech Industry Stock Outlook - Jan 2013 - Industry Outlook

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  34. Eli Lilly Beats Expectations - Analyst Blog

    January 29, 2013
    Eli Lilly & Company (LLY) reported fourth quarter 2012 adjusted earnings per share of 85 cents, well above the Zacks Consensus ...
  35. Market News Fails to Disappoint - Analyst Blog

    January 29, 2013
    As the first FOMC meeting of 2013 gets underway today, it is perhaps appropriate to acknowledge the Fed's contribution to ...
  36. Pfizer Tops, Guides In Line - Analyst Blog

    January 29, 2013
    Pfizer Inc. (PFE) posted fourth quarter earnings of 47 cents per share, 3 cents above the Zacks Consensus Estimate but 4% ...
  37. Ahead of Wall Street - January 29, 2013 - Ahead of Wall Street

    January 29, 2013
    Tuesday, January 29, 2013 As the first FOMC meeting of 2013 gets underway today, it is perhaps appropriate to acknowledge ...
  38. Merck's OAB Patch Gets FDA Nod - Analyst Blog

    January 28, 2013
    Merck (MRK) recently announced that it has received US Food and Drug Administration (FDA) approval for its transdermal patch, ...
  39. FDA Approves Novartis' Exjade - Analyst Blog

    January 25, 2013
    Novartis (NVS) recently announced that the US Food and Drug Administration (FDA) has approved Exjade (deferasirox) for the ...
  40. Novartis Beats on Revs, EPS In-Line - Analyst Blog

    January 24, 2013
    Swiss pharmaceutical giant Novartis (NVS) reported fourth quarter 2012 earnings per share of 84 cents, up 71% from the year-ago ...
  41. Pfizer Readies Zoetis For Market

    January 23, 2013
    Pfizer filed further details about its tentative spin-off of Zoetis, its animal health business.
  42. J&J Beats on EPS but Guidance Lags - Analyst Blog

    January 22, 2013
    Johnson & Johnson's (JNJ) fourth quarter 2012 earnings (excluding special items) of $1.19 per share were a couple of cents ...
  43. Allergan's Botox Label Expanded - Analyst Blog

    January 21, 2013
    Allergan Inc. (AGN) recently received a major boost with the US Food and Drug Administration (FDA) approving Botox (onabotulinumtoxinA) ...
  44. EU Expands J&J Zytiga Label - Analyst Blog

    January 16, 2013
    Johnson & Johnson's (JNJ) Janssen-Cilag International NV recently announced that the European Commission (EC) has granted ...
  45. Glaxo Seeks Albiglutide Approval - Analyst Blog

    January 15, 2013
    GlaxoSmithKline (GSK) recently announced the submission of a marketing application to the US Food and Drug Administration ...
  46. Merck to Stop Selling Tredaptive - Analyst Blog

    January 14, 2013
    Merck (MRK) recently announced that it is taking its cholesterol management drug, Tredaptive (extended-release niacin/laropiprant), ...
  47. Setback for ArQule, Shares Fall - Analyst Blog

    January 14, 2013
    ArQule Inc. (ARQL) and partner Daiichi Sankyo recently announced disappointing phase II results on oncology candidate, tivantinib ...
  48. J&J Drug Supported by FDA Panel - Analyst Blog

    January 14, 2013
    Janssen Research & Development, LLC, a Johnson & Johnson (JNJ) company, recently announced that the FDA's Endocrinologic ...
  49. Lilly to Go Solo with LY2605541 - Analyst Blog

    January 11, 2013
    Eli Lilly and Company (LLY) recently announced that it will be developing diabetes candidate, LY2605541, on its own. The ...
  50. Encouraging EPS Outlook from Lilly - Analyst Blog

    January 7, 2013
    Late last week, Eli Lilly and Company (LLY) provided its financial guidance for 2013 and commented on its 2012 guidance as ...
  51. Patent Challenge for Auxilium Pharma - Analyst Blog

    January 7, 2013
    Auxilium Pharmaceuticals, Inc. (AUXL) and Xstelos Holdings, Inc. (XTLS) recently received a notice from Upsher-Smith Laboratories, ...
  52. Positive Data on Alkermes Candidate - Analyst Blog

    January 4, 2013
    Alkermes plc (ALKS) recently announced positive results from a phase I study on its new antipsychotic candidate, ALKS 3831. ...
  53. NVO's Ryzodeg Approved in Japan - Analyst Blog

    December 28, 2012
    Denmark based Novo Nordisk (NVO) recently announced that it has received approval in Japan for its diabetes treatment, Ryzodeg ...
  54. Myriad Alleviates to Outperform - Analyst Blog

    December 21, 2012
    Following a strong first quarter result and an encouraging guidance, we upgrade our recommendation on Myriad Genetics (MYGN), ...
  55. NVO Progresses with Pipeline - Analyst Blog

    December 20, 2012
    Novo Nordisk (NVO) recently completed a phase IIIa study on IDegLira, which is a combination of Tresiba (insulin degludec) ...
  56. Merck Ties Up with GE Healthcare - Analyst Blog

    December 19, 2012
    Merck (MRK) is collaborating with GE Healthcare for the use of an investigational positron emission tomography (PET) imaging ...
  57. CHMP Negative on Isis' Kynamro - Analyst Blog

    December 17, 2012
    The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently did not recommend ...
  58. Isis Pharma, AstraZeneca Ink Deal - Analyst Blog

    December 14, 2012
    Isis Pharmaceuticals Inc. (ISIS) and AstraZeneca (AZN) recently announced that they have entered into an agreement to discover ...
  59. An End to Drug Patent Woes? - Analyst Blog

    December 14, 2012
    The US Supreme Court will soon hear a case which will determine whether "pay-for-delay" agreements between drug manufacturers ...
  60. Lilly Plans Trial for Solanezumab - Analyst Blog

    December 13, 2012
    Eli Lilly (LLY) recently provided an update on its plans for its Alzheimer's disease candidate, solanezumab. The company ...
  61. Myriad Teams Up with Sanofi - Analyst Blog

    December 11, 2012
    Myriad RBM, a wholly-owned subsidiary of molecular diagnostic company Myriad Genetics Inc. (MYGN), has recently collaborated ...
  62. Merck's Alzheimer's Drug Progresses - Analyst Blog

    December 10, 2012
    Merck (MRK) recently moved its Alzheimer's disease candidate, MK-8931, into a phase II/III study (EPOCH). The study will ...
  63. Pharma & Biotech Stock Outlook - Dec 2012 - Zacks Analyst Interviews

    December 6, 2012
    The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The ...
  64. Pharma & Biotech Stock Outlook - Dec 2012 - Industry Outlook

    December 6, 2012
    The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The ...
  65. Elan Starts Phase II AD Study - Analyst Blog

    November 28, 2012
    Elan Corporation (ELN) recently initiated a phase II study on ELND005 (Study AG201) for the treatment of agitation/aggression ...
  66. CHMP Positive on Sanofi's Lyxumia - Analyst Blog

    November 21, 2012
    Sanofi (SNY) recently announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use ...
  67. MannKind Inks Deal with Colby - Analyst Blog

    November 15, 2012
    MannKind Corporation (MNKD) recently signed a license agreement with Colby Pharmaceutical Company granting the latter exclusive ...
  68. AZN's Forxiga Gets EU Approval - Analyst Blog

    November 15, 2012
    Recently, AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) announced that their type II diabetes candidate, Forxiga (dapagliflozin) ...
  69. Teva Likely To Tread Water Ahead Of New Strategy

    November 5, 2012
    Teva has restructuring and growth opportunities, but the risk is still elevated.
  70. Eli Lilly Misses but Affirms View - Analyst Blog

    October 24, 2012
    Eli Lilly & Company (LLY) reported third quarter 2012 adjusted earnings per share of 79 cents, missing the Zacks Consensus ...
  71. Stock Market News for October 16, 2012 - Market News

    October 16, 2012
    Strong September retail sales data coupled with better-than-expected quarterly results by Citigroup drove the benchmarks ...
  72. Healthcare Stocks, Including Abbott, Making Big Moves on October ...

    October 15, 2012
    The Nasdaq is up 0.3%, the S&P 500 has risen 0.3% and the Dow has climbed 0.3%, marking a bad morning for the market. The ...
  73. Eli Lilly Among Healthcare's Biggest Movers on October 9, 2012

    October 9, 2012
    The market is having a bad day so far. The Nasdaq has declined 1.7%; the S&P 500 is trading down 0.8%; and the Dow has fallen ...
  74. Lilly Up on Alzheimer's Data - Analyst Blog

    October 9, 2012
    Shares of Eli Lilly and Company (LLY) reached a 52-week high of $50.94 on Monday with the company reporting full results ...
  75. Merck KGaA Withdraws Erbitux MAA - Analyst Blog

    September 19, 2012
    Merck KGaA (MKGAF) recently announced the withdrawal of the marketing authorization application (MAA) to the European Medicines ...
  76. Eli Lilly Among Healthcare's Biggest Movers on August 27, 2012

    August 27, 2012
    The market is on the rise this morning. The Nasdaq is up 0.5%; the S&P 500 has risen 0.3%; and the Dow has climbed 0.1%. ...
  77. Healthcare Stocks, Including Eli Lilly, Making Big Moves on August ...

    August 24, 2012
    The Nasdaq has increased 0.6%, the S&P 500 has risen 0.5% and the Dow has moved up 0.6% on a good day for the market so far. ...
  78. Pfizer & JNJ End Bapineuzumab IV - Analyst Blog

    August 7, 2012
    Pfizer, Inc. (PFE) recently announced disappointing late-stage results on intravenous (IV) bapineuzumab. Bapineuzumab is ...
  79. Portfolio Pruning 101

    July 27, 2012
    MoneyShow's Tom Aspray takes an in-depth look at his successful Charts in Play Portfolio, as he looks to take profits on ...
  80. Lilly Beats & Lifts View Again - Analyst Blog

    July 25, 2012
    Eli Lilly & Company (LLY) reported second quarter 2012 adjusted earnings per share of 83 cents, 6 cents above the Zacks Consensus ...
  81. Pfizer, J&J Drug Fails in 1st Study - Analyst Blog

    July 24, 2012
    Pfizer, Inc. (PFE) recently announced highly-awaited top-line results on Alzheimer's disease candidate, bapineuzumab. Pfizer ...
  82. Biggest Healthcare Sector Movers for July 24, 2012, Including ...

    July 24, 2012
    On a bad day for the market, the Nasdaq has decreased 0.2%, the S&P 500 has declined 0.5% and the Dow is down 0.6%. The healthcare ...
  83. Earnings Preview: Bristol-Myers - Analyst Blog

    July 23, 2012
    Biopharmaceutical giant  Bristol-Myers Squibb Company (BMY) is all set to unveil  its second quarter 2012 results before ...
  84. Merck KGaA's Erbitux Disappoints - Analyst Blog

    July 10, 2012
    Merck KGaA (MKGAF) recently announced that Erbitux failed to achieve its primary endpoint in the phase III EXPAND trial, ...
  85. FDA Approves Qiagen's KRAS Test - Analyst Blog

    July 9, 2012
    Molecular diagnostics solutions provider, Qiagen (QGEN) recently got the nod of the U.S. Food and Drug Administration ("FDA") ...
  86. FDA Label Expansion for Erbitux - Analyst Blog

    July 9, 2012
    Bristol-Myers Squibb Company (BMY) and partner Eli Lilly & Company (LLY) recently announced that they have received approval ...
  87. Four S&P Stocks With A P/E Ratio Under 12

    June 27, 2012
    Using the P/E ratio of a stock can be a great step to finding value.
  88. Time To Buy Pharmaceuticals?

    June 2, 2012
    While you never can be certain of what the future will bring, clearly Eli Lilly, Gilead Sciences, Biogen Idec all have improving ...
  89. Stocks Pay Huge Dividends

    May 31, 2012
    Stocks that consistently pay sizable dividends offer important advantages to individual investors. Here are five worth a ...
  90. Best Dividends For Your Dollar

    April 30, 2012
    Stocks that consistently pay sizable dividends offer important advantages to individual investors. Here are five worth a ...
  91. Four S&P Stocks With Under A 12 P/E Ratio

    February 14, 2012
    There are still quality blue chip-like names that offer decent valuations and, in some cases, excellent yields.
  92. Health Care's Highest Yields

    January 30, 2012
    Some of the biggest and highest-yielding drug stocks are declining near attractive buy levels, giving income-oriented investors ...
  93. Four S&P Stocks With A 10 P/E Ratio

    December 28, 2011
    There are still quality blue chip-like names that offer decent valuations and, in some cases, excellent yields.
  94. Sanofi's Investment Prospects

    December 21, 2011
    Sanofi has emerged as an unheralded value in pharmaceuticals.
  95. If Pipelines Matter, Novartis Should Be Looking Healthy

    November 30, 2011
    When a company like Novartis comes down the road with a healthy pipeline, the Street seems to respond with worries.
  96. Should Pfizer Forget R&D Altogether?

    November 2, 2011
    Pfizer has to convince the Street that it can still grow, but the stock is cheap for now.
  97. Big Values In Big Pharma

    November 1, 2011
    The major pharmaceutical firms now represent value. These companies could represent a great income play.
  98. Merck's Penance Has Gone On Long Enough

    October 31, 2011
    Merck won't grow fast, but it's quality is undervalued. It's time for investors to reevaluate it.
  99. 5 Dividend Darlings

    October 20, 2011
    Strong dividend payers could form the best defense in an unsure market.
  100. What Is Walgreen's Next Trick?

    September 30, 2011
    Walgreen is doing okay today, but tomorrow is a much bigger question.
  101. Vivus Tries A New Path

    September 21, 2011
    Vivus takes a more pragmatic approach to getting Qnexa to market.
  102. Find Your Way Back With Dividends

    September 12, 2011
    Strong dividend payers could form the best defense in an unsure market.
  103. Top Dividend Stocks Owned By The Pros

    August 2, 2011
    Selecting from the top dividend stocks owned by professional investors may give your portfolio a boost.
  104. Top Healthcare Dividend Stocks

    July 26, 2011
    Healthcare stocks are one attractive area in which you can reap dividend income while waiting for the sector to grow.
  105. Earnings Preview for July 21

    July 20, 2011
    Here are four companies that will be releasing their earnings on July 21.
  106. Should Investors Circle Back To Cubist?

    July 19, 2011
    Cubist is hitting its targets, but it needs a more exciting pipeline.
  107. 10 Drug Stocks for Safety and Yields

    June 26, 2011
    Big pharma is an attractive destination for traders and investors looking for safety, yields, and solid value in the current ...
  108. More To Merck Than Meets The Eye?

    June 22, 2011
    Merck is set up to exceed low-ball estimates.
  109. 5 S&P 500 Stocks With Huge Dividends

    June 10, 2011
    We combed through the S&P 500 to find 5 high yielding stocks.
  110. Best Dividends For Your Dollar

    May 10, 2011
    Stocks that consistently pay sizable dividends offer important advantages to individual investors. Here are five worth a ...
  111. Novo Nordisk Still One Of The Best Around

    May 3, 2011
    Novo Nordisk is one of the best pharmaceutical companies in the world - and it's priced accordingly.
  112. 4 Important Earnings Announcements For April 18

    April 15, 2011
    Earnings reports are significant events for every stock. Here are 4 earnings announcement for April 18 to check out.
  113. Four S&P Stocks With A 10 P/E Ratio

    April 12, 2011
    There are still quality blue chip-like names that offer decent valuations and, in some cases, excellent yields.
  114. On The Hunt For Dividend Stocks

    February 15, 2011
    Interested investors can find dividends in a variety of shapes and sizes.
  115. Top 3 Sectors For Value Investors

    February 8, 2011
    As the U.S. economy has recovered, so have the equity markets. Learn the best-value sectors that investors should focus on.
  116. Pfizer Pleases Investors

    February 3, 2011
    The market is praising Pfizer's decision to cut back on R&D and focus funds on repurchasing its attractively-priced stock.
  117. A Foursome Of Pharma Earnings Suggests Business Is Still Tough

    January 31, 2011
    There's little growth to excite pharma investors, but there is more value here than some realize.
  118. 7 Important Earnings Announcements For January 27

    January 26, 2011
    Earnings reports are significant events for every stock. Here are 7 earnings announcement for January 27 that you should ...
  119. MannKind And The FDA - Here We Go Again

    January 20, 2011
    MNKD got another FDA setback in its attempts to bring inhaled insulin to the market.
  120. Undervalued Large Cap Stocks

    December 30, 2010
    undervalued stocks
  121. Novartis Brings Alcon Into The Fold

    December 16, 2010
    Novartis closes the deal for Alcon.
  122. Pfizer Ready To Create Value

    December 15, 2010
    Overall, Pfizer is a company with a cheap stock price, earnings power and numerous options to reward shareholders.
  123. Can New Leadership Rejuvenate Big Pharma?

    December 8, 2010
    Will another new drug company CEO make a difference in a stagnating industry?
  124. Merck Makes A Smart Buy

    December 3, 2010
    Merck is making an exciting bet on a possible diabetes breakthrough.
  125. 5-Star Dividend Stocks

    November 26, 2010
    Stocks that consistently pay sizable dividends offer important advantages to individual investors. Here are five worth a ...
  126. 7 S&P 500 Stocks With Huge Dividends

    November 4, 2010
    We combed through the S&P 500 to find 7 of the highest yielding stocks.
  127. Allergan Winning Wall Street's Beauty Pageant

    November 3, 2010
    Allergan's earnings aren't special, but the stock is basking in Wall Street's love. Is it simply a case of lipstick on a ...
  128. Vivus Gets An Encouraging “No”

    October 29, 2010
    Vivus gets a big boost of encouragement from a benign FDA rejection.
  129. Is Now The Time To Buy Pharmaceuticals?

    October 29, 2010
    While you never can be certain of what the future will bring, clearly Eli Lilly, Gilead Sciences, Biogen Idec all have improving ...
  130. J&J Will Get Well Soon

    October 25, 2010
    At the current time, finding investment appeal in Johnson & Johnson's stock is difficult.
  131. Trick Or Treat For Biodel?

    October 21, 2010
    Will Biodel's upcoming PDUFA date give investors a treat or just leave a sour taste?
  132. Pfizer's King For A Day

    October 14, 2010
    Pfizer does a deal that is good, but not great.
  133. Top-Heavy Pharmaceuticals

    August 27, 2010
    Investors should keep an eye on how much drug companies rely on its top sellers.
  134. 5-Star Dividend Stocks

    July 22, 2010
    Stocks that consistently pay sizable dividends offer important advantages to individual investors. Here are five worth a ...
  135. Novartis On The Right Track

    July 19, 2010
    With recent sales increases and a solid pipeline, Novartis deserves a spot on the watchlist of anybody looking at Big Pharma.
  136. What Ails Amgen?

    June 30, 2010
    Amgen is being treated like just another Big Pharma laggard, but analysis suggests there is more growth potential here.
  137. Amgen's New Double-Play Drug

    June 8, 2010
    Amgen hopes for a boost in revenue from their just-approved multi-purpose drug, Prolia.
  138. Will Adaptive Design Change The BioPharma World?

    May 13, 2010
    Adaptive design is an idea whose time has come, and investors in biotechs and pharmaceuticals should stand to benefit.
  139. GlaxoSmithKline On Simmer

    April 30, 2010
    Glaxo's earnings look powerful, but is this really a top idea in the pharma sector?
  140. Gilead's Uncertain Future

    April 26, 2010
    Despite a coming wave of patent expirations, Gilead's stock still deserves a further look.
  141. Four S&P Stocks Under An 8 P/E Ratio

    April 2, 2010
    Forget about capturing returns from last year's stock prices. Yet even today, quality blue chip-like names offer decent valuations ...
  142. What Is The Value Of An Employee

    February 5, 2010
    The "return on employee" is a valid way to determine the value of a company's staff within an industry.
  143. Pfizer Feeling Frisky

    February 4, 2010
    Investors are worried about Lipitor's patent running out, but Pfizer has many other ways to give your portfolio a rise.
  144. A Trio Of High Yielders With Strong Cash Positions

    July 21, 2009
    Here are some safe dividends with a 5% dividend or more, a rarity these days for stocks in the S&P 500.
  145. Dividend Divas For July 14

    July 14, 2009
    Companies that pay a high dividend show their commitment to returning money to shareholders. Here we drill down into the ...
  146. It Pays To Advertise

    June 29, 2009
    During hard times, some companies reduce advertising while others increase it. Which method is the most effective?
  147. Four Breakout Biotech Stocks

    June 12, 2009
    These four biotech stocks are currently on the upswing.
  148. Big Pharma's Buying Spree

    April 24, 2009
    A look at recent merger and acquisition activity in the pharmaceutical sector and possible opportunities if the trend continues.
  149. Johnson & Johnson Should Return To Form

    April 16, 2009
    Though J&J hasn't been delivering consistent, steady growth as of late, this company should prove healthy in the future.
  150. Is Lorillard Poised To Smoke?

    April 7, 2009
    Lorillard Tobacco Company looks promising to survive the current economic downturn, despite increasing cigarette taxes.
  151. Forest Labs Faces Patent Expirations

    January 23, 2009
    This pharma faces patent expirations on its two key drugs, but its valuation reflects these risks and the firm has appealing ...
  152. One More Step For MannKind

    December 4, 2008
    This biotech's inhaled insulin seems to work, but will it sell?
  153. Bristol-Myers Squibb Could Rise To Old Highs

    November 19, 2008
    Flush with cash and growth prospects, Bristol makes the case to be a core healthcare holding.
  154. Wyeth's Day In Court

    November 6, 2008
    Wythe and other drug companies are anxiously awaiting the outcome a product labeling liability case before the U.S. Supreme ...
  155. 5 Large Volume Stocks For Oct. 6 Morning

    October 6, 2008
    A list of five stocks trading on large volume Monday morning.
  156. Pfizer's Exubera Pflops (PFE)

    October 25, 2007
    Pfizer took a $2.8 billion hit when it cancelled Exubera from its product line - is the worst now over, or is there more ...
  157. Is Big Pharma Bad Medicine?

    March 26, 2007
    They’ve had plenty of opportunity to get their act together – some have, and some haven’t. However, are there any major drug ...
  158. Generic Manufacturers Go After Big Pharma

    March 14, 2007
    Generic drug manufacturers continue pose a potent threat to the established "big pharma" companies.
  159. Bristol-Myers Hurt By Plavix, Saved By Demographics (BMY)

    November 16, 2006
    Despite BMY's recent struggles with its Plavix sales, favorable demographics make the stock a good investment to consider.
Investing News
  1. Outside the Box: Hoisington Investment Mgmt Review and Outlook, Q1 2014

    Outside the Box: Hoisington Investment Management Quarterly Review and Outlook, First Quarter ...
  2. Why Stick With Energy Stocks? (Hint: Geopolitical Risk)

    By most fundamental measures, oil prices should be declining. Russ explains why they’re on ...
  3. Bad Investor Behavior: Overemphasizing Experience

    Behavioral finance researchers have discovered that our personal experiences disproportionately ...
  4. Thoughts From The Frontline: Every Central Bank For Itself

    Thoughts from the Frontline: Every Central Bank for Itself
  5. 3 Dumb Ways to Borrow Money

    Money — everyone needs it, but not everyone has it. Many people who find themselves in a ...
  6. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
Trading Center